Travere Therapeutics (TVTX) risk factors, FY2024 10-K

Risks Related to the Commercialization of Our Products

1. 01Our future prospects are highly dependent upon our ability to successfully develop and execute commercialization strategies for our products, including FILSPARI, and to attain market acceptance among physicians, patients and healthcare payers
2. 02IgAN, it is difficult to estimate FILSPARI’s market potential or the time it will take to increase patient and physician awareness of FILSPARI and change current treatment paradigms
3. 03In order to operate our business and increase adoption and sales of our products, we need to continue to develop our commercial organization, including maintaining a highly experienced and skilled workforce with qualified sales representatives
4. 04The commercial success of our products depends on them being considered to be effective drugs with advantages over other therapies
5. 05We face substantial generic and other competition, and our operating results will suffer if we fail to compete effectively
6. 06Healthcare reform initiatives, unfavorable pricing regulations, and changes in reimbursement practices of third-party payers or patients' access to insurance coverage could affect the pricing of and demand for our products
7. 07We are dependent on third parties to manufacture and distribute our products
8. 08Governments outside the United States tend to impose strict price controls and reimbursement approval policies, which may adversely affect our prospects for generating revenue
9. 09We may not be able to rely on orphan drug exclusivity for our products
10. 10Guidelines and recommendations published by various organizations may impact the use of our products

Risks Related to the Development of our Product Candidates

1. 11Our clinical trials are expensive and time-consuming and may fail to demonstrate the safety and efficacy of our product candidates
2. 12Before obtaining regulatory approval for the sale of any of our current or future product candidates, we must subject these product candidates to extensive nonclinical and clinical testing to demonstrate their safety and efficacy for humans. Clinical trials are expensive, time-consuming and may take years to complete
3. 13Success in nonclinical testing and early clinical trials does not ensure that later clinical trials will be successful
4. 14Communications and/or feedback from regulatory authorities related to our current or planned future clinical trials does not guarantee any particular outcome from or timeline for regulatory review, and expedited regulatory review pathways may not actually lead to faster development or approval
5. 15Interim, topline and preliminary data from our clinical trials that we announce or publish may change materially as more patient data become available and audit and verification procedures are complete
6. 16We and/or a collaborative partner are or will be subject to ongoing regulatory obligations and continued regulatory review for our approved products and any product candidates that receive regulatory approval
7. 17The third-party clinical investigators and contract research organizations that we rely upon to conduct our clinical trials may not be diligent, careful or timely, and may make mistakes, in the conduct of our trials

Risks Related to our Products and Product Candidates

1. 18Our products may not achieve or maintain expected levels of market acceptance or commercial success
2. 19REMS in the future following sufficient experience with FILSPARI and if supported by the data, there is no guarantee that the data will support this endeavor, or even if we believe it does, that the FDA will agree with it
3. 20The market opportunities for our products and product candidates may be smaller than we believe they are
4. 21Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization
5. 22We do not currently have patent protection for certain of our commercial products. If we are unable to obtain and maintain protection for the intellectual property relating to our technology and products, their value will be adversely affected
6. 23interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection
7. 24We expect to rely on orphan drug status to develop and commercialize certain of our products and product candidates, but our orphan drug designations may not confer marketing exclusivity or other expected commercial benefits
8. 25Any therapies we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business
9. 26If we are unable to obtain and maintain coverage and adequate reimbursement from governments or third-party payers for any products that we may develop or if we are unable to obtain acceptable prices for those products, our prospects for generating revenue and achieving profitability will suffer
10. 27We face potential product liability exposure far in excess of our limited insurance coverage
11. 28We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. Our operating results will suffer if we fail to compete effectively
12. 29Materials necessary to manufacture our products and product candidates may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our products and product candidates

Risks Related to Our Business

1. 30Our limited operating history makes it difficult to evaluate our future prospects, and our profitability in the future is uncertain
2. 31We depend on a highly experienced and skilled workforce to grow and operate our business. If we are unable to attract, retain and engage our employees, we may not be able to grow effectively
3. 32Health epidemics or pandemics could materially adversely affect our business, results of operations and financial condition
4. 33We will likely experience fluctuations in operating results and could incur substantial losses
5. 34Negative publicity regarding any of our products could impair our ability to market any such product and may require us to spend time and money to address these issues
6. 35We may not have sufficient insurance to cover our liability in any current or future litigation claims either due to coverage limits or as a result of insurance carriers seeking to deny coverage of such claims
7. 36We may need substantial funding and may be unable to raise capital when needed
8. 37The market price for shares of our common stock may be volatile and purchasers of our common stock could incur substantial losses
9. 38We may not receive some or all of the potential milestone and/or royalty payments from our corporate and licensing transactions
10. 39We may be unable to successfully integrate new products or businesses we may acquire
11. 40Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop
12. 41We may become involved in litigation matters, which could result in substantial costs, divert management's attention and otherwise have a material adverse effect on our business, operating results or financial condition
13. 42We are subject to significant ongoing regulatory obligations and oversight, which may result in significant additional expense and may limit our commercial success
14. 43requiring the reporting of certain information related to drug pricing; and requiring drug manufacturers to track and report information related to payments, gifts, compensation, and other items of value to physicians and other healthcare providers
15. 44If we are not able to obtain and maintain required regulatory approvals, we will not be able to commercialize our products, and our ability to generate revenue will be materially impaired
16. 45In the ordinary course of our business, we and the third parties with whom we work process proprietary, confidential, and sensitive data, including personal data (such as health-related data and data related to our clinical trials), intellectual property, and trade secrets (collectively, sensitive information)
17. 46Risks related to the use of artificial intelligence technologies could adversely affect our business, financial condition and/or operating results
18. 47Uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations could materially affect our tax obligations and effective tax rate
19. 48Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income and taxes may be subject to limitations
20. 49Our business could be negatively impacted by environmental, social and corporate governance (ESG) matters or our reporting of such matters
21. 50Framework is implemented in Northern Ireland on January 1, 2025, products falling within the scope of the EU centralized procedure can only be authorized through UK national authorization procedures in Great Britain
22. 51Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
23. 52Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations
24. 53We maintain our cash at financial institutions, often in balances that exceed federally insured limits

Risks Related to our Indebtedness and Investments

1. 54Our indebtedness could adversely affect our financial condition
2. 55We may be unable to raise the funds necessary to repurchase the 2025 Notes and 2029 Notes for cash following a fundamental change, or to pay any cash amounts due upon conversion, and our future indebtedness may limit our ability to repurchase the 2025 Notes and 2029 Notes or pay cash upon their conversion
3. 56A default under the 2025 Notes or 2029 Notes may have a material adverse effect on our financial condition
4. 57Provisions of the 2025 Notes and 2029 Notes could discourage an acquisition of us by a third party
5. 58Conversion of the Notes may dilute the ownership interest of existing stockholders, including holders who had previously converted their 2025 Notes or 2029 Notes
6. 59Unstable market, economic and geopolitical conditions may have serious adverse consequences on our business, financial condition and stock price